Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

Published:2018-01-22 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Lalani Aly-Khan A.,Xie Wanling,Martini Dylan J.,Steinharter John A.,Norton Craig K.,Krajewski Katherine M.,Duquette Audrey,Bossé Dominick,Bellmunt Joaquim,Van Allen Eliezer M.,McGregor Bradley A.,Creighton Chad J.,Harshman Lauren C.,Choueiri Toni K.

Funder

Foundation for the National Institutes of Health

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0315-0.pdf

Reference31 articles.

1. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(6):804–34.

2. Motzer RJ, Bacik J, Murphy BA, et al. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

3. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2005;23:832–41.